Success Metrics

Clinical Success Rate

64.3%

Based on 9 completed trials

Completion Rate

64%(9/14)

Active Trials

0(0%)

Results Posted

56%(5 trials)

Terminated

5(31%)

Phase Distribution

Ph phase_2

25%

Ph phase_3

19%

Ph phase_1

56%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution16 total trials

Phase 1Safety & dosage

9(56.3%)

Phase 2Efficacy & side effects

4(25.0%)

Phase 3Large-scale testing

3(18.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

56.3%

9 of 16 finished

Non-Completion Rate

43.8%

7 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(9)

Terminated(7)

Detailed Status

Completed9

Terminated5

Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

64.3%

Most Advanced

Phase 3

Trials by Phase

Phase 19 (56.3%)

Phase 24 (25.0%)

Phase 33 (18.8%)

Trials by Status

withdrawn213%

completed956%

terminated531%

Recent Activity

0 active trials

Showing 5 of 16

terminatedphase_3

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

NCT03068130

completedphase_2

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL

NCT03019185

completedphase_2

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

NCT02036970

terminatedphase_3

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

NCT03749447

completedphase_1

A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl

NCT01461161

View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials

NCT03068130Phase 3

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

Terminated

NCT03019185Phase 2

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL

Completed

NCT02036970Phase 2

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

Completed

NCT03749447Phase 3

An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

Terminated

NCT01461161Phase 1

A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl

Completed

NCT00529113Phase 1

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Terminated

NCT01551446Phase 1

Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes

Withdrawn

NCT01655186Phase 2

A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus

Withdrawn

NCT01549769Phase 1

Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes

Terminated

NCT01563562Phase 1

Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

Completed

NCT01503866Phase 1

A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects

Completed

NCT00529438Phase 1

RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies

Completed

NCT03550443Phase 3

A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study

Terminated

NCT04494646Phase 2

BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)